Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-093853
Filing Date
2024-08-08
Accepted
2024-08-08 16:01:29
Documents
76
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q eypt-20240630.htm   iXBRL 10-Q 2027857
2 EX-10.3 eypt-ex10_3.htm EX-10.3 55781
3 EX-31.1 eypt-ex31_1.htm EX-31.1 13365
4 EX-31.2 eypt-ex31_2.htm EX-31.2 13725
5 EX-32.1 eypt-ex32_1.htm EX-32.1 5870
6 EX-32.2 eypt-ex32_2.htm EX-32.2 5961
  Complete submission text file 0000950170-24-093853.txt   8536336

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eypt-20240630.xsd EX-101.SCH 1295219
78 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20240630_htm.xml XML 1445742
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51122 | Film No.: 241188036
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)